Stay updated on Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page

  1. Check
    today
    Change Detected
    Summary
    Removal of related topics on the page, including Lung cancer and MedlinePlus Genetics, which are navigational aids rather than core study details. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-31T02:56:03.000Z thumbnail image
  2. Check
    7 days ago
    Change Detected
    Summary
    Added Lung cancer and related topics (MedlinePlus Genetics), added Locations, and added sites in Alicante, Barcelona, Coruña, Navarre, and Vizcaya. Removed HHS Vulnerability Disclosure and several location pages (Alicante Locations, Barcelona Locations, Coruña Locations, Navarre Locations, Vizcaya Locations) and updated from Revision: v3.3.2 to v3.3.3.
    Difference
    0.7%
    Check dated 2025-12-24T02:20:56.000Z thumbnail image
  3. Check
    15 days ago
    No Change Detected
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page's related topics section no longer includes Lung cancer and MedlinePlus Genetics. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-12-02T17:20:13.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    Revision in the page footer updated from v3.2.0 to v3.3.2. This is a system update and does not alter the study information or eligibility criteria.
    Difference
    0.0%
    Check dated 2025-11-25T13:27:45.000Z thumbnail image
  7. Check
    43 days ago
    Change Detected
    Summary
    Added topic tags 'Lung cancer' and related 'MedlinePlus Genetics' topics to the page. Removed the government funding status notice about NIH operations.
    Difference
    0.5%
    Check dated 2025-11-18T07:19:38.000Z thumbnail image
  8. Check
    50 days ago
    Change Detected
    Summary
    The related topics section now omits Lung cancer and MedlinePlus Genetics, reducing navigational context but not changing the study’s core details; To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.1%
    Check dated 2025-11-11T03:09:59.000Z thumbnail image

Stay in the know with updates to Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Advanced NSCLC: 2nd Line Clinical Trial page.